Last reviewed · How we verify
Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study
The purpose of this study is to observe correction of haemoglobin (Hb) levels in patients receiving chemotherapy as a consequence of a solid tumour, a malignant lymphoma or a multiple myeloma and who are treated with Retacrit™.
Details
| Lead sponsor | Hospira, now a wholly owned subsidiary of Pfizer |
|---|---|
| Status | COMPLETED |
| Enrolment | 291 |
| Start date | 2010-12 |
| Completion | 2013-07 |
Conditions
- Chemotherapy-induced Symptomatic Anaemia
- Solid Tumours
- Malignant Lymphomas
- Multiple Myeloma
Primary outcomes
- Change and corrected Hemoglobin levels — 6 months
Participants who have hemoglobin values between 11 and 12 g/dl after 6 months of treatment.
Countries
Germany